PeptideStack
5.2kquestions
20kanswers
220users

Why does the constipation outlast the nausea by months when both are supposedly the same mechanism?

Asked 21 Aug 2024Modified 19 months agoViewed 29k times
50

The nausea followed exactly the pattern I was told to expect: bad for a fortnight after each dose step, better by week four, essentially gone by month five. The constipation has done nothing of the sort. It started around week three and it is now month eleven, unchanged, at a stable dose.

This is not a minor complaint. I have gone from a completely unremarkable daily pattern to something every three or four days that requires planning and, increasingly, pharmacological help. It is the thing about this drug I would most like to fix and the thing I have found least useful information about, presumably because nausea is more dramatic.

What I do not understand is the mechanism. Both symptoms are described as consequences of slowed gastrointestinal motility, and the nausea attenuates. If they share a mechanism, why does one adapt and the other not? And is there a dose relationship, because I would consider a lower dose for this if it would help.

What I have tried: more water, more fibre, more walking. The fibre made the bloating considerably worse and I stopped.

constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

14 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

44 questions
shareeditfollowflag
SS
askedswab_stopper16k1621 Aug 2024
3The fibre making it worse is a specific and informative observation, not a failure to try hard enough. – n_takahashi 10 days ago
2Nausea and constipation on this class are not the same mechanism, which is the answer to most of the question. – anouk_desmet 9 months ago
add a comment

3 Answers

Accepted answer first, then by votes
132

Accepted answer

They are not the same mechanism, which is why they have different time courses. Nausea is largely a central emetic phenomenon that adapts. Constipation is largely a peripheral motility plus reduced-input phenomenon, and while the motility component does attenuate somewhat, the reduced-input component gets worse over time rather than better, because it tracks your food intake and your food intake is the point of the drug.

The four contributors, and what each does over time

ContributorMechanismTrajectory over months
Delayed gastric emptying and slowed small-bowel transitVagally mediated, direct receptor effects on gut smooth muscle and enteric neuronsPartially attenuates over weeks to months
Reduced total food volumeLess residue enters the colon; stool volume falls; distension-triggered propulsive reflexes are triggered less oftenWorsens or persists, because intake stays low by design
Reduced fluid intakeLess eating means less drinking, and 20-30% of daily water intake normally comes from foodPersists unless actively corrected
Reduced dietary fibre in absolute termsSomeone eating 1,300 kcal eats less of everything, including fibre, even at unchanged fibre densityWorsens as intake falls

That second row is the crux, and it is worth stating plainly: a substantial part of constipation on this class is not a drug effect at all. It is an eating-less effect. Which is a consequence of the drug, but a mechanistically different one, and it does not adapt because nothing is adapting to it. The colon requires a certain volume of residue to generate the distension that triggers mass movements. Cut intake by 40% and you cut that volume, and no amount of receptor-level tachyphylaxis will replace it.

Why the difference in adaptation

The emetic response is a defensive reflex with a threshold, mediated through the area postrema, and defensive reflexes habituate: that is what they do, and it is adaptive not to keep vomiting in response to a persistent stimulus. Colonic transit is not a reflex with a threshold. It is a continuous mechanical process whose rate depends on smooth-muscle activity, enteric neural coordination, luminal content and water. There is nothing there to habituate. The receptor-level component may desensitise; the mechanical consequence of a smaller input does not.

This also explains a confusing observation: people who eat more have less constipation, and the improvement is immediate rather than gradual. That is the input term changing, not the drug wearing off.

The dose question

Constipation is dose related in the trials, but more weakly than nausea and, interestingly, non-monotonically in the same way. SURMOUNT-1 reported constipation in 16.8%, 17.1% and 11.7% of the 5, 10 and 15 mg arms against 5.8% on placebo [1]. The 15 mg arm reported less constipation than the 5 mg arm. STEP 1 reported 23.4% on semaglutide 2.4 mg against 9.5% on placebo [2].

The non-monotonicity is probably explained by diarrhoea, which is also common on this class and rises with dose more consistently than constipation does. At the top of the range a larger fraction of people sit on the loose end of the spectrum, so the constipation column falls.

What that means for you: a lower dose might help and is a legitimate conversation, but expect it to be partial, because the intake term will not change much while appetite suppression is preserved. The largest lever on constipation specifically is usually not the dose. It is the volume and composition of what you eat.

Why your fibre attempt made things worse

Predictable, and it deserves its own answer, so briefly: adding insoluble bulking fibre to a slow-transit colon with inadequate fluid gives you a larger, slower, harder mass and more gas. Bulking requires adequate water and adequate transit to help, and on this class you frequently have neither. That is not a sign you need more fibre. It is a sign bulking is the wrong lever.

What actually has support here

In rough order of expected yield, on the specific problem of slow transit with reduced intake:

  • Fluid, measured rather than intended. Not because water is a laxative, which it is not in a hydrated person, but because every other intervention on this list fails without it. Your fibre attempt almost certainly failed partly for this reason.
  • An osmotic agent, most commonly a macrogol or polyethylene glycol preparation. This is the best-evidenced pharmacological approach for chronic constipation generally, and it works by mechanism rather than by stimulation: it holds water in the lumen, softening content and increasing volume without depending on residue. That makes it a good mechanistic fit for a low-intake state. Osmotic laxatives have the strongest evidence base in chronic constipation of any class.
  • Magnesium salts, osmotic by the same principle. Cheap, widely used, and not benign in impaired kidney function.
  • Soluble, low-fermenting fibre rather than insoluble bulk, if fibre at all. Discussed in the fibre answer below.
  • Movement, modest evidence, good for you anyway, will not solve this alone.
  • Protein intake, indirectly. High-protein low-volume eating is characteristically constipating, and this population is correctly told to prioritise protein. The two goals conflict, genuinely rather than through poor adherence.

And the thing worth checking first: a change from daily to every three or four days over eleven months is worth mentioning to a clinician once, both to exclude the other causes of altered bowel habit and because prescription options for refractory chronic constipation are more effective than anything on a shelf.

edited 12 Sept 2024 by Dr_Priya_Raghunathan — clarified the distinction between purity and content

shareimprove this answerflag
DR
answered · acceptedDr_Priya_Raghunathan94k2481 Sept 2024
7Framing part of it as an eating-less effect rather than a drug effect is the reframe that made this tractable for me. – h_villanueva 7 months ago
6The 15 mg arm reporting less constipation than the 5 mg arm is a nice example of a safety table containing something counterintuitive. – mz_4113 5 months ago
The protein-versus-transit conflict is real and nobody warns you about it. – dead_volume 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
67

On fibre specifically, since it is the first thing everyone is told and it makes a meaningful minority of people worse. The evidence is better than "fibre is good for you" and more specific.

Fibre is not one thing

TypeExamplesMechanismGas productionFit for slow transit with low intake
Insoluble bulkingWheat bran, cellulose, vegetable skinsMechanical bulk, mildly irritant, speeds transit in a normal colonLowPoor. Needs adequate transit and water. Classic cause of worse bloating and harder stool in slow transit
Soluble, gel-forming, poorly fermentedPsyllium (ispaghula)Forms a viscous gel, holds water, softens without much fermentationLow to moderateBest of the fibres. The one with real trial evidence in chronic constipation
Soluble, highly fermentedInulin, fructo-oligosaccharides, chicory root, most added "prebiotic fibre"Fermented to gas and short-chain fatty acidsHighPoor. This is the category that produces the bloating people report. Also the category most often added to protein bars and shakes
Resistant starchCooled cooked potato and rice, green banana flourFermentedHighVariable, often poorly tolerated here
Non-fermented syntheticMethylcelluloseBulk with water retention, minimal fermentationLowReasonable, less evidence than psyllium

The evidence for psyllium in chronic constipation is reasonably good: randomised comparisons have found it superior to placebo and to wheat bran for stool frequency and consistency, and it is the fibre recommended in most functional gastrointestinal guidance on that basis. It has a genuine mechanistic advantage over bran here: it forms a gel and holds water rather than relying on mechanical bulk and transit.

The evidence against fibre in general is not that it does not work but that it works in the wrong population. Fibre trials recruit people with ordinary functional constipation. Slow-transit constipation is the subgroup that reliably does worse with bulking, and there is a reasonable literature showing that people with slow transit and with bloating-predominant symptoms deteriorate on fibre supplementation. If your dominant symptoms are bloating and distension rather than straining, fibre is the wrong intervention and adding more of it is not the answer to it not having worked.

A GLP-1 agonist creates exactly the physiology in which fibre underperforms: slowed transit, reduced fluid, reduced volume tolerance in the stomach, and a strong tendency to bloating. So the standard advice is being applied to the population least likely to benefit from it.

Practical version

  • If you try fibre, use psyllium rather than bran, start at a small fraction of the labelled dose, and increase over two to three weeks rather than in one step. Abrupt introduction is itself a cause of bloating.
  • Take it with a substantially larger volume of water than feels necessary. Insufficient fluid with a gel-forming fibre is genuinely counterproductive, and in rare cases of stricture or severe slow transit, bulking agents have caused obstruction.
  • Read the labels on protein products. Inulin and chicory root fibre are in a great many of them, and someone eating three protein bars a day is consuming a substantial fermentable fibre load without knowing it. This is a common hidden cause of bloating in this population.
  • If bloating and distension dominate, skip fibre and go to an osmotic agent instead. Those work without needing residue.
  • Note that your stomach volume tolerance is reduced, so bulking fibre competes with protein and with fluid for a limited space. That is a real constraint and it is worth allocating deliberately.
shareimprove this answerflag
RI
answeredrukhsana_iqbal14k2819 Dec 2024
The inulin-in-protein-bars point solved a two-month mystery for me. – birk_nordahl 14 days ago
2Psyllium started at a quarter dose and built up over a month worked where the same product at full dose had been unusable. – t_oyelaran 2 months ago
add a comment
39

Adding the osmotic versus stimulant distinction, since it determines what you should reach for and in what order, and the two are frequently treated as interchangeable.

Osmotic

Macrogol/polyethylene glycol preparations, lactulose, magnesium hydroxide and magnesium citrate. These retain water in the lumen by osmotic gradient. They increase stool water content and volume without requiring residue, without requiring intact propulsive function, and without stimulating anything.

  • Best evidence in chronic constipation of any laxative class. Macrogol has repeatedly outperformed lactulose in randomised comparisons for stool frequency and consistency.
  • Onset is typically one to three days, so it is not a rescue agent.
  • No credible tolerance or dependence, which is the main argument for using it as the maintenance agent rather than as an occasional one.
  • Lactulose is fermented and therefore gassy, which makes it a poor choice in a bloating-predominant picture. Macrogol is not fermented and is the better fit here.
  • Requires you to drink the water it is dissolved in. In someone with reduced fluid intake, an osmotic agent that draws water into the gut without replacement is not a good idea.

Stimulant

Senna, bisacodyl, sodium picosulfate. These act on enteric nerves and smooth muscle to increase propulsive activity and reduce absorption.

  • Effective, fast, onset typically 6-12 hours orally.
  • Also evidence-supported in chronic constipation; the old claim that they damage the colon or cause structural dependence with normal use is not well supported. What is well supported is cramping, urgency and unpredictability.
  • The practical objection in this context is different: a stimulant increases propulsion in a colon whose problem is partly insufficient content. That works, and it produces cramping, and it does not address the cause.
  • Reasonable as an intermittent rescue on top of an osmotic maintenance agent. Less reasonable as the only thing you do.

Others worth knowing about

  • Docusate, a stool softener, has surprisingly poor evidence and repeatedly fails to beat placebo. It is very widely used and probably should not be.
  • Glycerol suppositories and enemas work rectally and are useful for a hard distal stool, which is a specific and common problem that oral agents address slowly.
  • Prescription secretagogues and prokinetics exist for refractory chronic constipation and have randomised evidence behind them. That is a clinician conversation, and the point of mentioning them is that "I have tried everything" usually means everything on a supermarket shelf.

A sensible order of operations

  1. Fix fluid first, measured. Everything downstream depends on it.
  2. Osmotic agent as maintenance, titrated to effect rather than to the label.
  3. Consider psyllium if straining rather than bloating dominates, introduced slowly.
  4. Stimulant as intermittent rescue only.
  5. If none of that works after a fair trial, that is a clinical conversation rather than a shopping problem.

Nothing here is a treatment recommendation for any individual and laxative choice interacts with renal function, cardiac medication and other conditions. Magnesium loads in particular are not benign in impaired kidney function.

shareimprove this answerflag
PM
answeredp_mkhize41k13823 Sept 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.